Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Total Current Liabilities (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Total Current Liabilities for 5 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 36.61% to $9.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.5 million, a 36.61% decrease, with the full-year FY2024 number at $12.6 million, down 35.55% from a year prior.
  • Total Current Liabilities was $9.5 million for Q3 2025 at Lyra Therapeutics, down from $11.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $22.0 million in Q1 2022 to a low of $4.2 million in Q1 2021.
  • A 5-year average of $14.3 million and a median of $14.2 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 426.74% in 2022, then plummeted 42.09% in 2025.
  • Lyra Therapeutics' Total Current Liabilities stood at $18.2 million in 2021, then decreased by 20.69% to $14.5 million in 2022, then soared by 35.43% to $19.6 million in 2023, then tumbled by 35.55% to $12.6 million in 2024, then dropped by 24.95% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Total Current Liabilities are $9.5 million (Q3 2025), $11.2 million (Q2 2025), and $11.5 million (Q1 2025).